The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Placebo-controlled comparison of spirapril at 6, 12 and 24 mg/day in mild to severe essential hypertension.
In a double-blind , parallel-group study , 260 patients with mild to severe essential hypertension were r and omized to treatment with placebo or spirapril at 6 , 12 or 24 mg once daily for 6 weeks . When blood pressures were measured at the end of the dosing interval ( trough ) , all spirapril regimens had produced similar reductions in sitting systolic and diastolic blood pressures ( siSBP/siDBP ) which were significantly greater than those observed in placebo-treated patients . There were no relevant changes in resting heart rate in any of the study groups . At the study endpoint , the mean reductions in siSBP/siDBP were 14.9/11.5 mmHg with spirapril at 6 mg , 15.4/12.0 mmHg with spirapril at 12 mg and 17.8/12.4 mmHg with spirapril at 24 mg/day vs. 3.1/3.6 mmHg with placebo . In a subgroup of 122 patients , blood pressure was recorded at the end of the dosing interval and during the 8 hours immediately postdose to monitor the peak effects on blood pressure . All spirapril dosages produced similar reductions at peak with a mean decrease of siDBP of approximately 20 mmHg in comparison to baseline values vs 6 - 7 mmHg with placebo . The trough : peak ratios for 6 , 12 and 24 mg all lay between 60 % and 90 % for siSBP and siDBP , indicating that most of the peak effect was maintained at trough . Spirapril was well tolerated ; the adverse event profile was not different from that with placebo , and no dose-related adverse events were observed . ( ABSTRACT TRUNCATED AT 250 WORDS
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .